FDA OKs Genentech's Actemra to treat a rare childhood arthritis

04/17/2011 | American City Business Journals

The FDA approved Genentech's Actemra, or tocilizumab, to treat patients age 2 and older with active systemic juvenile idiopathic arthritis, or Still's disease. Actemra is given alone or with methotrexate, the agency said. The drug originally was approved early last year for adults who respond poorly to tumor necrosis factor antagonists.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN